Results from the safety lead-in for a phase II study of pembrolizumab in combination with binimetinib and bevacizumab in patients with refractory metastatic colorectal cancer (mCRC).

Christopher H. Lieu,Sarah Lindsey Davis,Stephen Leong,Alexis Diane Leal,Patrick Jud Blatchford,Gurprataap S. Sandhu,William T. Purcell,Sunnie S. Kim,Zoe Van De Voorde,Rachel Telles,Anne Martin,Tiffany Cull,Meredith Waring,Colin Reed,Chimmoua Lee,Amanda Siedem,Matthew R Lee,Todd M. Pitts,S. Gail Eckhardt,Wells A. Messersmith

Results from the safety lead-in for a phase II study of pembrolizumab in combination with binimetinib and bevacizumab in patients with refractory metastatic colorectal cancer (mCRC).

2020

4031Background: The majority of pts with mCRC have microsatellite stable (MSS) tumors with minimal response to PD-L1/PD-1 blockade. MEK inhibition and VEGF inhibition have immunomodulatory effects ...

Keywords:

Oncology
Bevacizumab
Colorectal cancer
Internal medicine
in patient
Phases of clinical research
Refractory
Pathology
Pembrolizumab
Binimetinib
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations